Journals / İnfeksiyon Dergisi / 2004 / Cilt: 18 - Sayı: 3

Determination of extended spectrum beta-lactamase in nosocomial strains of Pseudomdnas aeruginosa

Hastane infeksiyonu etkeni olan Pseudomonas aeruginosa suşlarında genişlemiş spektrumlu beta-laktamaz varlığının araştırılması

Pages
293–296
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The evaluation of ESBL activity in the nosocomial strains of antibiotic resistant P. aeruginosa can be useful to determine the appropriate antibiotic therapy and also the rational antibiotic usage policies in hospitals.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The purpose of the study was to determine the presence of extended spectrum beta-lactamase (ESBL) in nosocomial strains of Pseudomonas aeruginosa.
📊
Key Findings & Data:In 13 (12%) out of 105 P. aeruginosa isolates, a synergy was determined between ceftazidime, aztreonam, cefotaxime and amoxicillin-clavulanic acid.
💡
Conclusion & Impact:The evaluation of ESBL activity in the nosocomial strains of antibiotic resistant P. aeruginosa can be useful to determine the appropriate antibiotic therapy and also the rational antibiotic usage policies in hospitals.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The purpose of the study was to determine the presence of extended spectrum beta-lactamase (ESBL) in nosocomial strains of Pseudomonas aeruginosa. ESBL production was determined v.'ith the double disk synergy test. In 13 (12%) out of 105 P. aeruginosa isolates, a synergy was determined between ceftazidime, aztreonam, cefotaxime and amoxicillin-clavulanic acid. The evaluation of ESBL activity in the nosocomial strains of antibiotic resistant P. aeruginosa can be useful to determine the appropriate antibiotic therapy and also the rational antibiotic usage policies in hospitals.

Özet

Bu çalışmanın amacı, hastane infeksiyonu etkeni olarak izole edilen Pseudomonas aeruginosa suşlarında genişlemiş spektrumlu beta-laktamaz (GSBL) varlığı saptamak idi. Bu enzim üretiminin saptanması için çift disk sinerji yöntemi kullanılmıştır. İzole edilen 105 P. aeruginosa susundan 13'ünde (%12) seftazidim, aztreonam ve sefotaksim ile amoksisilin-klavulanik asit arasında sinerji saptanmıştır. Hastane infeksiyonu etkeni olarak izole edilen dirençli P. aeruginosa suşlarında GSBL varlığının bilinmesi, uygun antibiyotik tedavisinin belirlenmesinde ve hastanede rasyonel antibiyotik kullanım politikasının oluşturulmasında yol gösterici olacaktır.

🔖

Cite This Article

SEYMEN, D., SABA, R., MAMIKOĞLU, L., İNAN, D. (2022). Determination of extended spectrum beta-lactamase in nosocomial strains of Pseudomdnas aeruginosa. İnfeksiyon Dergisi, Cilt: 18 - Sayı: 3, 293–296. https://ajindex.com/articles/651749

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Livermore DM. Beta-lactamases ih laboratory and clinical resistance. Clin Microbiol flev1995; 8: 557-84
  2. Gür D. Beta-laktamazlar. Flora 1997; 2: 3 ek
  3. Jacoby GA, Medeiros AA. More extended spectrum beta-lactamases. Antimicrob Agents Chemother 1991; 35:1697-704
  4. Nordmann P, Ronco E, Naas T, Duport C, Michel-Briand CY, Labia R. Characterization of a novel extended-spectrum beta-lactamase from. Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 962-9
  5. Watanabe M, lyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35:147-51
  6. Hall LMC, Livermore DM, Gür D, Akova M, Akalın HE. OXA-11, an extended spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37:1637-44. ?• Hancock REW. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998; 27 (Suppl 1): S93-9
  7. Bradford PA. Extended-spectrum beta lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51
  8. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16:128-40
  9. Horan TC, Gaynes RP, Martone WY, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections. 1992: A modification of CDC definitions of surgical wound ifections. Infect Control Hosp Epidemiol 1992; 13:606-8
  10. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. 9th ed. Approved Standard M100-S9. Pennsylvania: NCCLS, 1999
  11. Katsanis GP, Spargo J, Ferraro MJ, Sutton L, Jacoby GA. Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases. J Clin Microbiol 1994; 32: 691-6
  12. Philippon A, Labia R, Jacoby GA. Extended spectrum beta-lactamases. Antimicrob Agents Chemother 1989; 33:1131-6
  13. Danel F, Hall LMC, Gür D, Akalın HE, LivermoreDM. Transferable production of PER-1 beta-lactamase in Pseudomonas aeruginosa. J Antimicrob Chemother 1995; 35:281-94
  14. Vahaboğlu H, Hall LMC, Mülazimoğlu L, Dodanlı S, Yıldırım I, Livermore DM. Resistance to extended-spectrum cephalosphorins, caused by PER-1 beta-lactamase in Salmonella typhimurium from Istanbul, Turkey. J Med Microbiol 1995; 43: 294-9
  15. Vahaboğlu H, Dodanlı S, Eroğlu C, et a